Qiagen (QGEN) received a Buy rating and a EUR51.00 price target from Kepler Capital analyst Oliver Reinberg on January 12. The company’s shares closed last Thursday at $53.19, close to its 52-week high of $55.27.
Reinberg has an average return of 5.9% when recommending Qiagen.
According to TipRanks.com, Reinberg is ranked #7049 out of 7227 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for Qiagen with a $56.36 average price target.
See today’s analyst top recommended stocks >>
Based on Qiagen’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $484 million and net profit of $16.91 million. In comparison, last year the company earned revenue of $383 million and had a GAAP net loss of $161 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.
